Industry
Biotechnology
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Avi Kapoor
August 15, 2024 | 11:23 am
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 11:50 am
Portfolio Pulse from Benzinga Insights
May 28, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Insights
May 17, 2024 | 12:07 pm
Portfolio Pulse from Avi Kapoor
May 17, 2024 | 11:29 am
Portfolio Pulse from Benzinga Newsdesk
May 14, 2024 | 10:48 am
Portfolio Pulse from Benzinga Newsdesk
May 13, 2024 | 6:56 pm
Portfolio Pulse from Benzinga Newsdesk
May 13, 2024 | 11:37 am
Portfolio Pulse from Benzinga Insights
March 28, 2024 | 12:00 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.